The effect of reporting methods for dosing times on the estimation of pharmacokinetic parameters of escitalopram. - Wikidata - awgldk - TriplyDB

The effect of reporting methods for dosing times on the estimation of pharmacokinetic parameters of escitalopram.

The effect of reporting methods for dosing times on the estimation of pharmacokinetic parameters of escitalopram.

http://www.wikidata.org/entity/Q37207545

about

Common selective serotonin reuptake inhibitor side effects in older adults associated with genetic polymorphisms in the serotonin transporter and receptors: data from a randomized controlled trial.Relation of serotonin transporter genetic variation to efficacy of escitalopram for generalized anxiety disorder in older adults Antidepressant exposure as a predictor of clinical outcomes in the Treatment of Resistant Depression in Adolescents (TORDIA) study.Pharmacokinetically and clinician-determined adherence to an antidepressant regimen and clinical outcome in the TORDIA trial.Population pharmacokinetics of perphenazine in schizophrenia patients from CATIE: impact of race and smoking.A scoping review of studies comparing the medication event monitoring system (MEMS) with alternative methods for measuring medication adherence.Escitalopram reduces attentional performance in anxious older adults with high-expression genetic variants at serotonin 2A and 1B receptors.

P2860

Q30665994-073A9C60-6893-4E6C-9D1F-54634C9E0D74 Q34685706-3687329B-EC7B-44D2-AF36-7ED15F09698B Q36703044-E4263742-252E-4186-8B4F-E3B711C9E6BA Q36752052-8926F581-1E92-44C3-98CA-2B688EF75331 Q36828536-50A13C46-2B2D-4DF3-8E57-24512C044B1A Q37030734-A8A8E0C7-6628-42F0-B166-D0B6F792CC9E Q37669003-577544B8-F557-43DB-9877-2E63DF1D9218

P2860

The effect of reporting methods for dosing times on the estimation of pharmacokinetic parameters of escitalopram.

http://www.wikidata.org/entity/Q37207545

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on February 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

The effect of reporting method ...... ic parameters of escitalopram.

@en

The effect of reporting method ...... ic parameters of escitalopram.

@nl

type

label

The effect of reporting method ...... ic parameters of escitalopram.

@en

The effect of reporting method ...... ic parameters of escitalopram.

@nl

prefLabel

The effect of reporting method ...... ic parameters of escitalopram.

@en

The effect of reporting method ...... ic parameters of escitalopram.

@nl

P1433

Q37207545-46F5548B-364E-4915-9A89-F280772E4C03

P1476

Q37207545-69A93F54-B8A5-4759-844A-C54C3CC01097

P2093

Q37207545-0CD70523-1228-46D1-9E78-456CB2E883A8

Q37207545-2D69158C-038E-46BD-BD60-6A7C8DDE1493

Q37207545-4776DC88-3EC3-4698-8054-26A8778B2F77

Q37207545-4A0C6F6D-5F4C-4478-861A-649B5705CBA9

Q37207545-5C2C2E31-34D7-44AE-9F04-EE81BB826BA7

Q37207545-6440C8A4-3044-4720-8BEA-1A0112282840

Q37207545-98158CBA-3F06-480E-B495-9618D7921F78

Q37207545-A0E5CC2A-17D0-4419-BDCD-96DDEC1A1142

Q37207545-B7F30F8A-7B97-43FF-A801-8ADF99B3CEF6

Q37207545-BFE974B8-66B2-43B2-BFC6-8FD6C8D0759C

P2860

Q37207545-0C977364-7F29-47EE-A68A-7F558E6EFFD7

Q37207545-1051D852-17B9-4024-9894-E39D688583CD

Q37207545-17C11C5C-9452-4BE4-941B-EAD6E88643A5

Q37207545-1B7E92D4-BFE7-481E-9E42-A6FA2D446CE5

Q37207545-1C28944E-B9BB-4C59-A57C-A09EA4065EEE

Q37207545-29E919C0-B6DE-4647-AFAE-859FAAC85E2F

Q37207545-33A2C057-3F90-4D0A-9F31-A2C8951BF864

Q37207545-5D7A8BAD-37B0-4D14-847C-61C59E19ED1D

Q37207545-663C54D0-B459-4E98-B188-56AA2C8C8F69

Q37207545-680AE023-F400-4386-ACDD-8285FB7A8122

P304

Q37207545-08ABB270-FB39-486E-8992-9EA253915A7F

P31

Q37207545-2E1B7677-A781-41DE-95D7-F63416C27759

P356

Q37207545-2E16EFB3-AF01-4099-BF0F-77BAA26F9642

P433

Q37207545-80246D0E-738E-4B05-A432-B79B156126B5

P478

Q37207545-13481DCE-12CB-4265-8561-69D37315A4D5

P50

Q37207545-48F7C555-0043-479E-867A-638D0A16340D

P577

Q37207545-D7870908-FC1A-4A1A-9FEA-59271B6C9FA3

P5875

Q37207545-FD9E6C10-8B87-415B-ABCD-AD5949949D51

P698

Q37207545-86D33788-75E4-4908-894E-981B0F88D62B

P932

Q37207545-1E28F6D8-9A5F-4D24-AC87-75EC48279289

P356

0091270008327538

P1433

The Journal of Clinical Pharmacology

P1476

The effect of reporting method ...... ic parameters of escitalopram.

@en

P2093

Bruce G Pollock

http://www.w3.org/2001/XMLSchema#string

David J Kupfer

http://www.w3.org/2001/XMLSchema#string

Ellen Frank

http://www.w3.org/2001/XMLSchema#string

Gail Kepple

http://www.w3.org/2001/XMLSchema#string

Jeff Florian

http://www.w3.org/2001/XMLSchema#string

Marc R Gastonguay

http://www.w3.org/2001/XMLSchema#string

Margaret Kirshner

http://www.w3.org/2001/XMLSchema#string

Robert R Bies

http://www.w3.org/2001/XMLSchema#string

Yan Feng

http://www.w3.org/2001/XMLSchema#string

Yuyan Jin

http://www.w3.org/2001/XMLSchema#string

P2860

Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine

Estimation of population characteristics of pharmacokinetic parameters from routine clinical data

Adherence to Medication

Successful projection of the time course of drug concentration in plasma during a 1-year period from electronically compiled dosing-time data used as input to individually parameterized pharmacokinetic models.

Escitalopram : a review of its use in the management of major depressive and anxiety disorders.

Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial.

Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study.

The clinical pharmacokinetics of escitalopram.

Treatment of anxiety and depression in transplant patients: pharmacokinetic considerations.

The odds that clinically unrecognized poor or partial adherence confuses population pharmacokinetic/pharmacodynamic analyses.

P304

176-184

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0091270008327538

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

49

http://www.w3.org/2001/XMLSchema#string

P50

Andrea Fagiolini

P577

2009-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23959395

http://www.w3.org/2001/XMLSchema#string

P698

19179296

http://www.w3.org/2001/XMLSchema#string

P932

2688454

http://www.w3.org/2001/XMLSchema#string